Human papilloma virus clinical trials
How each study uses Human papilloma virus is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BV601
- 1
Studies by the year they started
5 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Washington University School of Medicine (1) · Xiamen University (1) · Merck Sharp & Dohme LLC (1) · Simon Dobson (1) · Wuhan BravoVax Co., Ltd. (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (1) · Hepatitis A virus (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)
Studies
Open first, then newest update. How each study uses Human papilloma virus is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human VaccinesActive, not recruitingPhase 4Washington University School of MedicineNCT07493460Written as nonavalent HPV vaccine (HPV)
- Phase I Clinical Trial of a Candidate HPV VaccineStatus unknownPhase 1Wuhan BravoVax Co., Ltd.NCT05672966Written as Human papillomavirus (HPV) Vaccine
- Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent VaccineCompletedPhase 2Xiamen UniversityNCT01356823Written as 30μg HPV
- Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00092521Written as Human Papillomavirus (HPV) 16 Monovalent
- A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus VaccineCompletedPhase 3Simon DobsonNCT00501137Written as HPV (Human Papillomavirus) Vaccine
Codes
What other systems call Human papilloma virus · ClinicalTrials.gg INT014403
- UNII (FDA) 23CVL7WF4JHUMAN PAPILLOMAVIRUSConfirmed FDA, Wikidata
- RxNorm 1311095One source FDA
- Wikidata Q69999790Human papilloma virusConfirmed FDA, Wikidata
- NCI Thesaurus C14226Human PapillomavirusConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 23CVL7WF4J | HUMAN PAPILLOMAVIRUS | Confirmed FDA, Wikidata |
| RxNorm | 1311095 | — | One source FDA |
| Wikidata | Q69999790 | Human papilloma virus | Confirmed FDA, Wikidata |
| NCI Thesaurus | C14226 | Human Papillomavirus | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.